CN104131108A - LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer - Google Patents
LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer Download PDFInfo
- Publication number
- CN104131108A CN104131108A CN201410397937.7A CN201410397937A CN104131108A CN 104131108 A CN104131108 A CN 104131108A CN 201410397937 A CN201410397937 A CN 201410397937A CN 104131108 A CN104131108 A CN 104131108A
- Authority
- CN
- China
- Prior art keywords
- primer
- lncrna
- sequence
- seq
- quantitative pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of biology, and in particular relates to a group of LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer, related kits and application thereof. The group of LncRNA biomarkers for diagnosing human lung adenocarcinoma and/or human colorectal cancer comprises uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174. The LncRNA biomarkers for diagnosing the human lung adenocarcinoma and/or human colorectal cancer can be used for distinguishing human early lung adenocarcinoma and human colorectal cancer, the AUC of the biomarkers for distinguishing early lung adenocarcinoma from normally paired lung tissues can reach 0.978, and the sensitivity and the specificity are respectively 92% and 98%. The AUC of the biomarkers for diagnosing a colorectal cancer sample can reach 0.963, and the sensitivity and the specificity are respectively 94.4% and 88.9%.
Description
Technical field
The present invention relates to biological technical field, particularly relate to lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis LncRNA biomarker, related kit and their purposes.
Background technology
Nonsmall-cell lung cancer is the first cause that causes whole world cancer associated death.It mainly comprises four kinds of histological subtypes: gland cancer, squamous cell carcinoma, large cell carcinoma and other (neuroendocrine carcinoma, innocent tumour etc.).The five year survival rate of nonsmall-cell lung cancer is lower than 15%, and early diagnosis can effectively reduce its mortality ratio.Early detection adenocarcinoma of lung is even more important, because it is modal nonsmall-cell lung cancer type.Heredity and the molecule imbalance mechanism of understanding adenocarcinoma of lung are the keys for adenocarcinoma of lung early diagnosis.
Colorectal cancer is one of common malignant tumor of digestive tract, and for the 2nd frequently-occurring malignant tumour of west economy developed country, in China, colorectal cancer accounts for the 2nd of digestive tract cancer.Most of colorectal cancer patients does not have symptom in early days, exceedes and when 75% patient makes a definite diagnosis, has belonged to late period.Excavate the relevant new bio mark of colorectal cancer and contribute to further to illustrate its pathogenesis, also can provide novel targets for human colorectal diagnosis and treatment simultaneously.
Nearest research shows that 90% genome is transcribed into non-coding RNA.Non-coding RNA is considered to " transcribing noise " at first.But increasing evidence shows that these non-coding RNAs have important biological action in many physiological processes.Non-coding RNA can be divided into short chain non-coding RNA (being less than 200bp) and long-chain non-coding RNA (being longer than 200bp).Long-chain non-coding RNA (LncRNA) can be divided into antisense long non-coding RNA, intron non-coding RNA (LincRNA), the relevant LncRNA of promotor and non-translational region LncRNA.Previous result of study shows, LncRNA plays an important role in various kinds of cell and biological procedures, and for example propagation, cell cycle, karyomit(e) are reinvented and histone modification.In addition, their unconventionality expression is relevant to kinds of tumors, comprises mammary cancer, cancer of the stomach, hepatocellular carcinoma and prostate cancer.But the relation between expression and adenocarcinoma of lung and the colorectal cancer of the biological function of LncRNA in adenocarcinoma of lung and colorectal cancer and LncRNA is also in the unknown stage.
Summary of the invention
The shortcoming of prior art in view of the above, the object of the present invention is to provide lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis to use LncRNA biomarker, for solving the problems of the prior art.LncRNA biomarker provided by the present invention has very high sensitivity and specificity for human lung adenocarcinoma and Human colorectal carcinoma, especially the early stage adenocarcinoma of lung of people and/or Human colorectal carcinoma are had to good detection effect, can be used as the detection of novel biomarker for adenocarcinoma of lung and/or colorectal cancer.
For achieving the above object and other relevant objects, first aspect present invention provides lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis to use LncRNA biomarker, and described LncRNA biomarker comprises: uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174.
Preferably, the described human lung adenocarcinoma early stage adenocarcinoma of lung of behaving, the described Human colorectal carcinoma early stage colorectal cancer of behaving.
The sequence of described uc001gzl.3 is as shown in Seq ID No:1;
The sequence of described ENST00000434223 is as shown in Seq ID No:2;
The sequence of described uc004bbl.1 is as shown in Seq ID No:3;
The sequence of described ENST00000540136 is as shown in Seq ID No:4;
The sequence of described NR_034174 is as shown in Seq ID No:5.
Preferably, described LncRNA biomarker also comprises: ENST00000568243, uc001gch.1, NR_047562, ENST00000442037 and NR_038125.
The sequence of described ENST00000568243 is as shown in Seq ID No:6;
The sequence of described uc001gch.1 is as shown in Seq ID No:7;
The sequence of described NR_047562 is as shown in Seq ID No:8;
The sequence of described ENST00000442037 is as shown in Seq ID No:9;
The sequence of described NR_038125 is as shown in Seq ID No:10.
Second aspect present invention provides the purposes of described LncRNA biomarker in the diagnosing tumor medicine of preparation or screening human lung adenocarcinoma and/or Human colorectal carcinoma.
Third aspect present invention provides lineup's adenocarcinoma of lung and/or Human colorectal carcinoma to diagnose the combination with LncRNA primer, marker, and described LncRNA primer comprises: the reverse transcription primer of LncRNA, uc001gzl.3 primer, ENST00000434223 primer, uc004bbl.1 primer, ENST00000540136 primer, NR_034174 primer.
Preferably, the reverse transcription primer of described LncRNA is random primer.
Preferably, uc001gzl.3 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:11, primer after the quantitative PCR of sequence as shown in SEQ ID No:12; ENST00000434223 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:13, primer after the quantitative PCR of sequence as shown in SEQ ID No:14; Uc004bbl.1 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:15, primer after the quantitative PCR of sequence as shown in SEQ ID No:16; ENST00000540136 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:17, primer after the quantitative PCR of sequence as shown in SEQ ID No:18; NR_034174 primer comprises primer after primer before the quantitative PCR of sequence as shown in SEQ ID No:19, the quantitative PCR of sequence as shown in SEQ ID No:20.
Preferably, described marker is SYBR Green.
Preferably, described LncRNA primer also comprises: ENST00000568243 primer, uc001gch.1 primer, NR_047562 primer, ENST00000442037 primer and NR_038125 primer.
Preferred, ENST00000568243 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:21, primer after the quantitative PCR of sequence as shown in SEQ ID No:22; Uc001gch.1 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:23, primer after the quantitative PCR of sequence as shown in SEQ ID No:24; NR_047562 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:25, primer after the quantitative PCR of sequence as shown in SEQ ID No:26; ENST00000442037 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:27, primer after the quantitative PCR of sequence as shown in SEQ ID No:28; NR_038125 primer comprises primer after primer before the quantitative PCR of sequence as shown in SEQ ID No:29, the quantitative PCR of sequence as shown in SEQ ID No:30.
Purposes in LncRNA primer described in fourth aspect present invention provides, the diagnosing tumor medicine that is combined in preparation or screening human lung adenocarcinoma and/or Human colorectal carcinoma of marker.
Fifth aspect present invention provides the tumor diagnosis kit of a kind of human lung adenocarcinoma and/or Human colorectal carcinoma, comprises described LncRNA primer, the combination of marker.
Preferably, described test kit also can comprise dNTP, random primer, reductive agent, RNase inhibitor, ThermoScript II, MgCl
2with one or more the combination in PCR damping fluid etc.
Sixth aspect present invention provides a kind of LncRNA chip that detects human lung adenocarcinoma and/or Human colorectal carcinoma, it is characterized in that, described LncRNA chip comprises solid phase carrier and is fixed on the probe of the LncRNA biomarker as claimed in claim 1 on solid phase carrier.
Those skilled in the art can be rule of thumb, and design can detect the probe of relevant LncRNA biomarker, the fluorescent probe being widely used as this area etc.Specifically, described fluorescent probe can be oligonucleotide probe, and described oligonucleotide probe is corresponding to the part or all of sequence of LncRNA.
LncRNA biomarker is used in human lung adenocarcinoma provided by the present invention and/or Human colorectal carcinoma diagnosis, can be used to distinguish the early stage adenocarcinoma of lung of people and Human colorectal carcinoma.Its AUC that distinguishes early stage adenocarcinoma of lung and pairing normal lung tissue can reach 0.978, significance is higher than these 5 LncRNAs AUC (p<0.05) of the early stage adenocarcinoma of lung of diagnosis separately, its ROC curve shows that these 5 LncRNAs diagnose the sensitivity of early stage adenocarcinoma of lung and specificity to be respectively 92% and 98%, and significance is sensitivity and the specificity (p<0.05) for adenocarcinoma of lung diagnosis higher than single LncRNA.And also can reach 0.963 for its AUC of diagnosis of colorectal cancer sample, sensitivity and specificity are respectively 94.4% and 88.9%, illustrate that the combination of LncRNAs provided by the present invention can also be served as the biomarker that colorectal cancer detects.
Brief description of the drawings
Fig. 1 is shown as 10 LncRNAs of the present invention and joins together to distinguish training set (n=50) adenocarcinoma of lung and the ROC graphic representation of normal lung tissue that matches thereof;
Fig. 2-A is shown as 5 LncRNAs of the present invention and joins together to distinguish training set (n=50) adenocarcinoma of lung and the ROC graphic representation of normal lung tissue that matches thereof; Fig. 2-B is shown as 5 LncRNAs of the present invention and joins together to distinguish checking collection (n=63) adenocarcinoma of lung and the ROC graphic representation of normal lung tissue that matches thereof.
Fig. 3 is shown as 10 LncRNAs of the present invention and joins together to distinguish colorectal cancer and match the ROC graphic representation of normal colorectal carcinoma.
Embodiment
Below, by specific specific examples explanation embodiments of the present invention, those skilled in the art can understand other advantages of the present invention and effect easily by the disclosed content of this specification sheets.The present invention can also be implemented or be applied by other different embodiment, and the every details in this specification sheets also can be based on different viewpoints and application, carries out various modifications or change not deviating under spirit of the present invention.
Before further describing the specific embodiment of the invention, should be understood that protection scope of the present invention is not limited to following specific specific embodiments; It is also understood that the term using in the embodiment of the present invention is in order to describe specific specific embodiments, instead of in order to limit the scope of the invention; In specification sheets of the present invention and claims, unless explicitly pointed out in addition in literary composition, singulative " ", " one " and " this " comprise plural form.
In the time that embodiment provides numerical range, unless should be understood that the present invention is otherwise noted, between two end points of each numerical range and two end points, any one numerical value all can be selected.Unless otherwise defined, the same meaning that all technology that use in the present invention and scientific terminology and those skilled in the art of the present technique understand conventionally.The concrete grammar that uses in embodiment, equipment, material, grasp according to those skilled in the art to prior art and record of the present invention, can also realize the present invention with any method, equipment and material similar to the method described in the embodiment of the present invention, equipment, material or prior art that be equal to.
Unless otherwise indicated, in the present invention, disclosed experimental technique, detection method, preparation method all adopt the routine techniques of molecular biology, biological chemistry, chromatin Structure and analysis, analytical chemistry, cell cultures, recombinant DNA technology and the association area of the art routine.These technology are existing perfect explanation in existing document, specifically can be referring to MOLECULAR CLONING:A LABORATORY MANUAL such as Sambrook, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel etc., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; The series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol.304, Chromatin (P.M.Wassarman and A.P.Wolffe, eds.), Academic Press, San Diego, 1999; With METHODS IN MOLECULAR BIOLOGY, Vol.119, Chromatin Protocols (P.B.Becker, ed.) Humana Press, Totowa, 1999 etc.
Embodiment 1
1 clinical sample is collected:
Collect the freezing flesh tissue sample of early stage adenocarcinoma of lung and the pairing normal lung tissue 113 thereof of during the 2011-2014 of Zhongshan Hospital Attached to Fudan Univ, filing right.All patients all have informed consent to participating in scientific research.
2 LncRNA quantitative PCR experiments:
2.1 RNA extracting and quantitative PCRs
Utilize Trizol extracted total RNA from frozen tissue, RNA is carried out quantitatively with microbody integral light photometer.
2.2 reference genes and primer
Reference gene is selected GAPDH, and the primer sequence of GAPDH and one group of LncRNA biomarker provided by the present invention is as shown in table 1:
The primer sequence that table 1 quantitative PCR uses
2.3 reverse transcription reaction
Use SuperScript III First Strand Synthesis System test kit to carry out reverse transcription, RNA initial amount is 1 μ g, the consumption of reverse transcription reaction component is as shown in table 2, reaction conditions: at 65 DEG C, hatch 5min, at least place 1min after completing on ice; In products therefrom, add again reverse transcription reaction mixing liquid, mix rear at 25 DEG C, hatch respectively at 10min, 50 DEG C, to hatch at 50min, 85 DEG C hatch 5min, the consumption of reverse transcription reaction mixing liquid is as shown in table 3; After completing, in each reaction products therefrom, add 1 μ l RNaseH, hatch 20min at 37 DEG C after cryopreservation for subsequent use.
Table 2 reverse transcription reaction component
Table 3 reverse transcription reaction mixing liquid (mix)
2.4 real-time quantitative PCR reactions
Quantitative PCR uses LightCycler480SYBR Green I master, and quantitatively instrument is LightCycler480.Reaction system is as shown in table 4, reaction conditions step as shown in table 5, each real-time quantitative PCR reaction and to complying three repetitions:
Table 4 real-time quantitative PCR premixed liquid
Table 5 real-time quantitative PCR thermal cycling reference value
Use SPSS 17.0 softwares to carry out statistical study to data.Data represent with the form of mean+SD, unless there is special explanation.In adenocarcinoma of lung and its pairing normal lung tissue, the differential expression of lncRNA statistics is used the method for paired sample t inspection, and all p values are bilateral, and p<0.05 has been considered to statistical significance.
2.5 10 LncRNAs distinguish the capability evaluation of adenocarcinoma of lung and pairing normal lung tissue thereof
We utilize ROC curve to assess the ability of this 10 LncRNAs (gene ENST00000568243, uc001gch.1, ENST00000434223, uc004bbl.1, NR_047562, ENST00000540136, ENST00000442037, NR_038125, NR_034174 and uc001gzl.3) differentiation adenocarcinoma of lung and pairing normal lung tissue thereof.Single LncRNA is 0.721-0.853 for the AUC of adenocarcinoma of lung diagnosis, and sensitivity is 66-87%, and specificity is 62-86% (as shown in table 6).We join together these 10 LncRNAs for the diagnosis of 50 pairs of adenocarcinoma of lung samples, and its AUC can reach 0.994 (as Fig. 1), and sensitivity and specificity are 96%.
The diagnostic result of 10 LncRNAs of table 6 in training set (50 pairs of samples)
1p value and AUC are with obtaining after reference gene GAPDH normalization method.
2.6.1 5 LncRNAs distinguish adenocarcinoma of lung and match the capability evaluation of normal lung tissue
We utilize ROC curve to assess the ability of 5 LncRNAs (ENST00000540136, NR_034174, uc001gzl.3, uc004bbl.1 and ENST00000434223) differentiation adenocarcinoma of lung and pairing normal lung tissue thereof.These 5 LncRNAs combine the AUC that distinguishes early stage adenocarcinoma of lung and match normal lung tissue can reach 0.978 (as shown in Fig. 2-A), and significance is higher than these 5 LncRNAs AUC (p<0.05) of the early stage adenocarcinoma of lung of diagnosis separately.ROC area under curve shows that these 5 LncRNAs diagnose the sensitivity of early stage adenocarcinoma of lung and specificity to be respectively 92% and 98%, and significance is sensitivity and the specificity (p<0.05) for adenocarcinoma of lung diagnosis higher than single LncRNA.
2.6.2 5 LncRNAs distinguish another group adenocarcinoma of lung and the capability evaluation of normal lung tissue that matches thereof
The detection characteristic of we these 5 LncRNAs that checking filters out from training set in other one group of 63 routine adenocarcinoma of lung sample and pairing normal lung tissue (checking collection) thereof.These 5 LncRNAs have significance differential expression (p<0.001) in adenocarcinoma of lung and pairing normal lung tissue thereof in all.Single LncRNA is 0.719-0.882 for detection of the AUC of adenocarcinoma of lung, and sensitivity is 77.8-85.2%, and specificity is 60.3-84.1% (table 7).These 5 LncRNAs joint-detection 63 can reach 0.987 (Fig. 2-B) to the AUC of adenocarcinoma of lung sample, sensitivity is 96.8%, specificity is 92.1%, and this equal significance is higher than the detectivity (p<0.05) of any single LncRNA.And this group LncRNAs has similar detectivity in two groups of independent samples (training set and checking collection), illustrate that this group LncRNAs can be used as the biomarker of adenocarcinoma of lung early detection.
The diagnostic result of 5 LncRNA of table 7 in checking collection (63 pairs of samples)
1p value and AUC are with obtaining after reference gene GAPDH normalization method.
Embodiment 2
1 clinical sample is collected:
Collect the freezing flesh tissue sample of the attached Ruijin Hospital of the Shanghai Communications University colorectal cancer of 2013 and the normal colorectal carcinoma 18 that matches thereof right.All patients all have informed consent to participating in scientific research.
2 LncRNA quantitative PCR experiments:
2.1 RNA extracting and quantitative PCRs
Utilize Trizol extracted total RNA from frozen tissue, RNA is carried out quantitatively with microbody integral light photometer.
2.2 reference genes and primer
Reference gene is selected GAPDH, and the primer sequence of reference gene and each LncRNA biomarker is as shown in the table 1 in embodiment 1.
2.3 reverse transcription reactions, real-time quantitative PCR reaction
Concrete grammar, step and the reaction system of reverse transcription reaction, real-time quantitative PCR reaction are identical with embodiment 1.Use SPSS 17.0 softwares to carry out statistical study to data.Data represent with the form of mean+SD, unless there is special explanation.In colorectal cancer and the normal colorectal carcinoma of its pairing, the differential expression of lncRNA statistics is used the method for paired sample t inspection, and all p values are bilateral, and p<0.05 has been considered to statistical significance.
2.4 10 LncRNAs distinguish colorectal cancers and match the capability evaluation of normal colorectal carcinoma
We utilize ROC curve to assess the ability that these 10 LncRNAs (gene ENST00000568243, uc001gch.1, ENST00000434223, uc004bbl.1, NR_047562, ENST00000540136, ENST00000442037, NR_038125, NR_034174 and uc001gzl.3) distinguish colorectal cancer and match normal colorectal carcinoma.Single LncRNA is 0.750-0.889 for the AUC of diagnosis of colorectal carcinoma, and sensitivity is 66.7%-88.9%, and specificity is 55.6%-83.3% (as shown in table 8).We join together these 10 LncRNAs for the diagnosis of 18 pairs of colorectal cancer samples, its AUC can reach 0.963 (as Fig. 3), sensitivity and specificity are respectively 94.4% and 88.9%, illustrate that these LncRNAs can be used as the biomarker that colorectal cancer detects completely.
Diagnostic result in 10 LncRNAs colorectal cancers of table 8 (18 pairs of samples)
1p value and AUC are with obtaining after reference gene GAPDH normalization method.
The above; it is only preferred embodiment of the present invention; not to any formal and substantial restriction of the present invention; should be understood that; for those skilled in the art; do not departing under the prerequisite of the inventive method, also can make some improvement and supplement, these improvement and the supplementary protection scope of the present invention that also should be considered as.All those skilled in the art, without departing from the spirit and scope of the present invention, a little change of making when utilizing disclosed above technology contents, the equivalent variations of modifying and developing, be equivalent embodiment of the present invention; Meanwhile, the change of any equivalent variations that all foundations essence technology of the present invention is done above-described embodiment, modification and differentiation, all still belong in the scope of technical scheme of the present invention.
Claims (12)
1. LncRNA biomarker is used in lineup's adenocarcinoma of lung and/or Human colorectal carcinoma diagnosis, and described LncRNA biomarker comprises: uc001gzl.3, ENST00000434223, uc004bbl.1, ENST00000540136 and NR_034174.
2. LncRNA biomarker is used in the diagnosis of human lung adenocarcinoma as claimed in claim 1 and/or Human colorectal carcinoma, it is characterized in that the described human lung adenocarcinoma early stage adenocarcinoma of lung of behaving, the described Human colorectal carcinoma early stage colorectal cancer of behaving.
3. human lung adenocarcinoma as claimed in claim 1 and/or Human colorectal carcinoma diagnosis LncRNA biomarker, it is characterized in that, described LncRNA biomarker also comprises: ENST00000568243, uc001gch.1, NR_047562, ENST00000442037 and NR_038125.
4. the purposes of the LncRNA biomarker as described in claim as arbitrary in claim 1-3 in the diagnosing tumor medicine of preparation or screening human lung adenocarcinoma and/or Human colorectal carcinoma.
5. the combination of lineup's adenocarcinoma of lung and/or Human colorectal carcinoma LncRNA primer, marker for diagnosis, described LncRNA primer comprises: the reverse transcription primer of LncRNA, uc001gzl.3 primer, ENST00000434223 primer, uc004bbl.1 primer, ENST00000540136 primer, NR_034174 primer.
6. the combination of lineup's adenocarcinoma of lung as claimed in claim 5 and/or Human colorectal carcinoma LncRNA primer, marker for diagnosis, is characterized in that, the reverse transcription primer of described LncRNA is random primer.
7. the combination of lineup's adenocarcinoma of lung as claimed in claim 5 and/or Human colorectal carcinoma LncRNA primer, marker for diagnosis, it is characterized in that, uc001gzl.3 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:11, primer after the quantitative PCR of sequence as shown in SEQ ID No:12; ENST00000434223 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:13, primer after the quantitative PCR of sequence as shown in SEQ ID No:14; Uc004bbl.1 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:15, primer after the quantitative PCR of sequence as shown in SEQ ID No:16; ENST00000540136 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:17, primer after the quantitative PCR of sequence as shown in SEQ ID No:18; NR_034174 primer comprises primer after primer before the quantitative PCR of sequence as shown in SEQ ID No:19, the quantitative PCR of sequence as shown in SEQ ID No:20.
8. the combination of lineup's adenocarcinoma of lung as claimed in claim 5 and/or Human colorectal carcinoma LncRNA primer, marker for diagnosis, it is characterized in that, described LncRNA primer also comprises: ENST00000568243 primer, uc001gch.1 primer, NR_047562 primer, ENST00000442037 primer and NR_038125 primer.
9. the combination of lineup's adenocarcinoma of lung as claimed in claim 8 and/or Human colorectal carcinoma LncRNA primer, marker for diagnosis, it is characterized in that, ENST00000568243 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:21, primer after the quantitative PCR of sequence as shown in SEQ ID No:22; Uc001gch.1 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:23, primer after the quantitative PCR of sequence as shown in SEQ ID No:24; NR_047562 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:25, primer after the quantitative PCR of sequence as shown in SEQ ID No:26; ENST00000442037 primer comprises primer before the quantitative PCR of sequence as shown in SEQ ID No:27, primer after the quantitative PCR of sequence as shown in SEQ ID No:28; NR_038125 primer comprises primer after primer before the quantitative PCR of sequence as shown in SEQ ID No:29, the quantitative PCR of sequence as shown in SEQ ID No:30.
10. the purposes in the diagnosing tumor medicine that is combined in preparation or screening human lung adenocarcinoma and/or Human colorectal carcinoma of the LncRNA primer as described in claim as arbitrary in claim 5-9, marker.
The tumor diagnosis kit of 11. 1 kinds of human lung adenocarcinomas and/or Human colorectal carcinoma, comprises the LncRNA primer as described in claim as arbitrary in claim 5-9, the combination of marker.
12. one kind is detected the LncRNA chip of human lung adenocarcinoma and/or Human colorectal carcinoma, it is characterized in that, described LncRNA chip comprises solid phase carrier and is fixed on the probe of the LncRNA biomarker as described in the claim as arbitrary in claim 1-3 on solid phase carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410397937.7A CN104131108B (en) | 2014-08-13 | 2014-08-13 | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410397937.7A CN104131108B (en) | 2014-08-13 | 2014-08-13 | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104131108A true CN104131108A (en) | 2014-11-05 |
| CN104131108B CN104131108B (en) | 2016-06-29 |
Family
ID=51803957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410397937.7A Expired - Fee Related CN104131108B (en) | 2014-08-13 | 2014-08-13 | LncRNA biomarker is used in lineup's adenocarcinoma of lung and Human colorectal carcinoma diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104131108B (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104673797A (en) * | 2015-02-09 | 2015-06-03 | 苏州大学 | Long-chain non-coding RNA participating in ionizing radiation stress reaction of human cells and application thereof |
| CN105219770A (en) * | 2015-11-03 | 2016-01-06 | 中国科学院上海微系统与信息技术研究所 | LncRNA biomarker is used in the diagnosis of lineup's lung squamous cancer |
| CN105441433A (en) * | 2015-02-09 | 2016-03-30 | 苏州大学 | Long-chain non-coding RNA participating in ionizing radiation stress responses of human body cells and application thereof |
| CN105441447A (en) * | 2015-02-09 | 2016-03-30 | 苏州大学 | Long-chain non-coding RNA participating in ionizing radiation stress responses of human body cells and application thereof |
| CN105463070A (en) * | 2015-07-08 | 2016-04-06 | 上海市同仁医院 | Application of UCA1 genes in preparing product for diagnosing colorectal cancer |
| CN105462974A (en) * | 2015-02-09 | 2016-04-06 | 苏州大学 | Long-chain non-coding RNA participating in human cell ionization radiation stress responses and application thereof |
| CN106119405A (en) * | 2016-08-31 | 2016-11-16 | 广州万德基因医学科技有限公司 | The prognostic markers thing of a kind of pulmonary carcinoma, the method using this labelling prediction lung cancer for prognosis and application |
| CN106295246A (en) * | 2016-08-07 | 2017-01-04 | 吉林大学 | Find the lncRNA relevant to tumor and predict its function |
| CN106702009A (en) * | 2017-03-06 | 2017-05-24 | 北京泱深生物信息技术有限公司 | Application of lung adenocarcinoma related gene |
| CN106929577A (en) * | 2017-03-06 | 2017-07-07 | 山东省立医院 | A kind of lncRNA biomarker related to adenocarcinoma of lung |
| CN107043823A (en) * | 2017-05-26 | 2017-08-15 | 郴州市第人民医院 | A kind of related tumor markers of colorectal cancer and application |
| CN107190052A (en) * | 2017-01-25 | 2017-09-22 | 河北医科大学第四医院（河北省肿瘤医院） | The purposes of LOC101928926 genes |
| CN108950001A (en) * | 2018-08-31 | 2018-12-07 | 北京泱深生物信息技术有限公司 | A kind of molecular marker relevant to rectal adenocarcinoma occurrence and development |
| CN109266746A (en) * | 2018-09-17 | 2019-01-25 | 南京医科大学 | It is a kind of for expanding the primer pair and its application of LINC02253 gene |
| CN111455052A (en) * | 2020-04-21 | 2020-07-28 | 首都医科大学附属北京友谊医院 | Exosome RNA molecular marker combination for early diagnosis of colorectal cancer and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103146693A (en) * | 2013-02-26 | 2013-06-12 | 中南大学 | Long chain non-coding RNA (Ribonucleic Acid) gene and application method thereof |
| CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
| CN103952475A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Novel esophageal carcinoma (EC) marker gene detection and application |
| CN103952474A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Esophageal carcinoma (EC) diagnosis marker and application method thereof |
-
2014
- 2014-08-13 CN CN201410397937.7A patent/CN104131108B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103237901A (en) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarkers for theranostics |
| CN103146693A (en) * | 2013-02-26 | 2013-06-12 | 中南大学 | Long chain non-coding RNA (Ribonucleic Acid) gene and application method thereof |
| CN103952475A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Novel esophageal carcinoma (EC) marker gene detection and application |
| CN103952474A (en) * | 2014-03-27 | 2014-07-30 | 南京市第一医院 | Esophageal carcinoma (EC) diagnosis marker and application method thereof |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104673797B (en) * | 2015-02-09 | 2018-02-02 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN104673797A (en) * | 2015-02-09 | 2015-06-03 | 苏州大学 | Long-chain non-coding RNA participating in ionizing radiation stress reaction of human cells and application thereof |
| CN105441433A (en) * | 2015-02-09 | 2016-03-30 | 苏州大学 | Long-chain non-coding RNA participating in ionizing radiation stress responses of human body cells and application thereof |
| CN105441447A (en) * | 2015-02-09 | 2016-03-30 | 苏州大学 | Long-chain non-coding RNA participating in ionizing radiation stress responses of human body cells and application thereof |
| CN105441433B (en) * | 2015-02-09 | 2018-06-01 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN105462974A (en) * | 2015-02-09 | 2016-04-06 | 苏州大学 | Long-chain non-coding RNA participating in human cell ionization radiation stress responses and application thereof |
| CN105462974B (en) * | 2015-02-09 | 2018-06-01 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN105441447B (en) * | 2015-02-09 | 2018-05-29 | 苏州大学 | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction |
| CN105463070B (en) * | 2015-07-08 | 2018-12-28 | 上海市同仁医院 | Application of the UCA1 gene in preparation diagnosis colorectal cancer product |
| CN105463070A (en) * | 2015-07-08 | 2016-04-06 | 上海市同仁医院 | Application of UCA1 genes in preparing product for diagnosing colorectal cancer |
| CN105219770A (en) * | 2015-11-03 | 2016-01-06 | 中国科学院上海微系统与信息技术研究所 | LncRNA biomarker is used in the diagnosis of lineup's lung squamous cancer |
| CN105219770B (en) * | 2015-11-03 | 2018-09-25 | 中国科学院上海微系统与信息技术研究所 | Lineup's lung squamous cancer diagnosis LncRNA biomarkers |
| CN106295246A (en) * | 2016-08-07 | 2017-01-04 | 吉林大学 | Find the lncRNA relevant to tumor and predict its function |
| CN106119405B (en) * | 2016-08-31 | 2019-11-12 | 广州万德基因医学科技有限公司 | A kind of prognostic markers object of lung cancer, the method and application for using label prediction lung cancer for prognosis |
| CN106119405A (en) * | 2016-08-31 | 2016-11-16 | 广州万德基因医学科技有限公司 | The prognostic markers thing of a kind of pulmonary carcinoma, the method using this labelling prediction lung cancer for prognosis and application |
| CN107190052B (en) * | 2017-01-25 | 2019-02-12 | 河北医科大学第四医院（河北省肿瘤医院） | The purposes of LOC101928926 gene |
| CN107190052A (en) * | 2017-01-25 | 2017-09-22 | 河北医科大学第四医院（河北省肿瘤医院） | The purposes of LOC101928926 genes |
| CN106702009A (en) * | 2017-03-06 | 2017-05-24 | 北京泱深生物信息技术有限公司 | Application of lung adenocarcinoma related gene |
| CN106929577B (en) * | 2017-03-06 | 2020-05-26 | 山东省立医院 | lncRNA biomarker related to lung adenocarcinoma |
| CN106929577A (en) * | 2017-03-06 | 2017-07-07 | 山东省立医院 | A kind of lncRNA biomarker related to adenocarcinoma of lung |
| CN107043823B (en) * | 2017-05-26 | 2020-05-12 | 郴州市第一人民医院 | Tumor marker related to colorectal cancer and application |
| CN107043823A (en) * | 2017-05-26 | 2017-08-15 | 郴州市第人民医院 | A kind of related tumor markers of colorectal cancer and application |
| CN108950001A (en) * | 2018-08-31 | 2018-12-07 | 北京泱深生物信息技术有限公司 | A kind of molecular marker relevant to rectal adenocarcinoma occurrence and development |
| CN108950001B (en) * | 2018-08-31 | 2020-08-11 | 青岛泱深生物医药有限公司 | Molecular marker related to occurrence and development of rectal adenocarcinoma |
| CN109266746A (en) * | 2018-09-17 | 2019-01-25 | 南京医科大学 | It is a kind of for expanding the primer pair and its application of LINC02253 gene |
| CN109266746B (en) * | 2018-09-17 | 2020-04-28 | 南京医科大学 | Primer pair for amplifying LINC02253 gene and application thereof |
| CN111455052A (en) * | 2020-04-21 | 2020-07-28 | 首都医科大学附属北京友谊医院 | Exosome RNA molecular marker combination for early diagnosis of colorectal cancer and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104131108B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104131108A (en) | LncRNA biomarkers for diagnosing human lung adenocarcinoma and human colorectal cancer | |
| Barrow et al. | Epigenetic epidemiology of cancer | |
| Friemel et al. | Intratumor heterogeneity in hepatocellular carcinoma | |
| CN107447033B (en) | Colorectal cancer diagnosis biomarker and application thereof | |
| Kuhlmann et al. | Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer | |
| CN109439749B (en) | Exosome miRNA marker for colorectal cancer diagnosis and diagnosis kit | |
| CN104877998B (en) | The primer pair and kit of the long-chain non-coding RNA expression in long-chain non-coding RNA and detection cell and tissue | |
| WO2012170478A2 (en) | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof | |
| Kuo et al. | Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas | |
| CN101851682B (en) | MiRNA combination used for detecting esophageal squamous cell carcinoma and application thereof | |
| CN109055563B (en) | Colorectal cancer related circular RNA gene, colorectal cancer molecular marker and application thereof | |
| CN105219770B (en) | Lineup's lung squamous cancer diagnosis LncRNA biomarkers | |
| CN106148529B (en) | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof | |
| Yu et al. | Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules | |
| CN103320504A (en) | Detection of microRNAs in excreta as early diagnosis biomarker of lung cancer, colorectal cancer and bladder cancer | |
| CN107475258A (en) | A kind of RNAcircEPSTI1 and its application in three cloudy breast cancer | |
| CN107130027A (en) | Application of the biomarker in colorectal cancer | |
| CN113981083A (en) | Nucleic acid combination and kit for colorectal cancer gene methylation detection | |
| Yang et al. | Different methylation profiles between intestinal and diffuse sporadic gastric carcinogenesis | |
| CN101798599A (en) | Purpose of hsa-miR-150 | |
| Zhuang et al. | c-Met and RON expression levels in endometrial adenocarcinoma tissue and their relationship with prognosis | |
| Abou-Zeid et al. | Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer | |
| EP2247754A1 (en) | Colon cancer associated transcript 1 (ccat1) as a cancer marker | |
| CN111154880B (en) | Bladder cancer body fluid biopsy biomarker and application thereof | |
| CN109457033B (en) | Marker for colon cancer screening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160629 Termination date: 20180813 |